Cargando…
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386335/ https://www.ncbi.nlm.nih.gov/pubmed/28157218 http://dx.doi.org/10.1038/bcj.2017.1 |
| _version_ | 1782520748962742272 |
|---|---|
| author | Swords, R T Watts, J Erba, H P Altman, J K Maris, M Anwer, F Hua, Z Stein, H Faessel, H Sedarati, F Dezube, B J Giles, F J Medeiros, B C DeAngelo, D J |
| author_facet | Swords, R T Watts, J Erba, H P Altman, J K Maris, M Anwer, F Hua, Z Stein, H Faessel, H Sedarati, F Dezube, B J Giles, F J Medeiros, B C DeAngelo, D J |
| author_sort | Swords, R T |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5386335 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-53863352017-04-26 Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes Swords, R T Watts, J Erba, H P Altman, J K Maris, M Anwer, F Hua, Z Stein, H Faessel, H Sedarati, F Dezube, B J Giles, F J Medeiros, B C DeAngelo, D J Blood Cancer J Letter to the Editor Nature Publishing Group 2017-02 2017-02-03 /pmc/articles/PMC5386335/ /pubmed/28157218 http://dx.doi.org/10.1038/bcj.2017.1 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| spellingShingle | Letter to the Editor Swords, R T Watts, J Erba, H P Altman, J K Maris, M Anwer, F Hua, Z Stein, H Faessel, H Sedarati, F Dezube, B J Giles, F J Medeiros, B C DeAngelo, D J Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes |
| title | Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes |
| title_full | Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes |
| title_fullStr | Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes |
| title_full_unstemmed | Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes |
| title_short | Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes |
| title_sort | expanded safety analysis of pevonedistat, a first-in-class nedd8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386335/ https://www.ncbi.nlm.nih.gov/pubmed/28157218 http://dx.doi.org/10.1038/bcj.2017.1 |
| work_keys_str_mv | AT swordsrt expandedsafetyanalysisofpevonedistatafirstinclassnedd8activatingenzymeinhibitorinpatientswithacutemyeloidleukemiaandmyelodysplasticsyndromes AT wattsj expandedsafetyanalysisofpevonedistatafirstinclassnedd8activatingenzymeinhibitorinpatientswithacutemyeloidleukemiaandmyelodysplasticsyndromes AT erbahp expandedsafetyanalysisofpevonedistatafirstinclassnedd8activatingenzymeinhibitorinpatientswithacutemyeloidleukemiaandmyelodysplasticsyndromes AT altmanjk expandedsafetyanalysisofpevonedistatafirstinclassnedd8activatingenzymeinhibitorinpatientswithacutemyeloidleukemiaandmyelodysplasticsyndromes AT marism expandedsafetyanalysisofpevonedistatafirstinclassnedd8activatingenzymeinhibitorinpatientswithacutemyeloidleukemiaandmyelodysplasticsyndromes AT anwerf expandedsafetyanalysisofpevonedistatafirstinclassnedd8activatingenzymeinhibitorinpatientswithacutemyeloidleukemiaandmyelodysplasticsyndromes AT huaz expandedsafetyanalysisofpevonedistatafirstinclassnedd8activatingenzymeinhibitorinpatientswithacutemyeloidleukemiaandmyelodysplasticsyndromes AT steinh expandedsafetyanalysisofpevonedistatafirstinclassnedd8activatingenzymeinhibitorinpatientswithacutemyeloidleukemiaandmyelodysplasticsyndromes AT faesselh expandedsafetyanalysisofpevonedistatafirstinclassnedd8activatingenzymeinhibitorinpatientswithacutemyeloidleukemiaandmyelodysplasticsyndromes AT sedaratif expandedsafetyanalysisofpevonedistatafirstinclassnedd8activatingenzymeinhibitorinpatientswithacutemyeloidleukemiaandmyelodysplasticsyndromes AT dezubebj expandedsafetyanalysisofpevonedistatafirstinclassnedd8activatingenzymeinhibitorinpatientswithacutemyeloidleukemiaandmyelodysplasticsyndromes AT gilesfj expandedsafetyanalysisofpevonedistatafirstinclassnedd8activatingenzymeinhibitorinpatientswithacutemyeloidleukemiaandmyelodysplasticsyndromes AT medeirosbc expandedsafetyanalysisofpevonedistatafirstinclassnedd8activatingenzymeinhibitorinpatientswithacutemyeloidleukemiaandmyelodysplasticsyndromes AT deangelodj expandedsafetyanalysisofpevonedistatafirstinclassnedd8activatingenzymeinhibitorinpatientswithacutemyeloidleukemiaandmyelodysplasticsyndromes |